Skip to main content
JINLING PHARMACEUTICAL CO.,LTD logo

JINLING PHARMACEUTICAL CO.,LTD — Investor Relations & Filings

Ticker · 000919 ISIN · CNE0000010W5 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,771 across all filing types
Latest filing 2024-04-29 Board/Management Inform…
Country CN China
Listing Shenzhen Stock Exchange 000919

About JINLING PHARMACEUTICAL CO.,LTD

https://www.jlyy1999.com

Jinling Pharmaceutical Co., Ltd. specializes in the research, development, manufacture, and sale of pharmaceutical products, with a focus on chemical drugs and traditional Chinese medicine preparations. The company’s product portfolio primarily targets cardiovascular and cerebrovascular diseases, anti-tumor treatments, and digestive system health. A prominent product in its lineup is the Mailuoning Injection, utilized for treating various vascular conditions. In addition to its manufacturing operations, the company is involved in the management and operation of medical institutions, integrating clinical services with pharmaceutical production. Its business model emphasizes the synergy between drug development and healthcare service delivery to provide integrated medical solutions.

Recent filings

Filing Released Lang Actions
独立董事2023年度述职报告（王广基，换届离任）
Board/Management Information Classification · 95% confidence The document is titled as an "Independent Director 2023 Annual Work Report" for Jinling Pharmaceutical Co., Ltd. It details the independent director's activities, attendance at board and shareholder meetings, committee participation, communication with auditors, and evaluation of company governance and financial reporting during the 2023 fiscal year. The content is a detailed report of the independent director's duties and observations rather than an announcement or a brief summary. It does not contain financial statements or earnings data but focuses on governance and oversight activities. This aligns with the category of Board/Management Information (MANG), which includes announcements or reports related to board members and senior management activities. The document is not a full annual report, audit report, or regulatory filing, nor is it a proxy or voting result announcement. Therefore, the best classification is MANG with high confidence.
2024-04-29 Chinese
金陵药业股份有限公司章程（2024年4月）
Governance Information Classification · 100% confidence The document is the Articles of Association (章程) of Jinling Pharmaceutical Company Limited, detailing the company's organizational structure, shareholder rights, board of directors, management, and governance rules. It includes extensive provisions on shares, shareholder meetings, board responsibilities, and internal governance. The document is a comprehensive governance framework rather than a financial report, earnings release, or announcement. It is not a report publication announcement or a short notice but a full legal document outlining governance practices. Therefore, it fits the category of Governance Information (CGR).
2024-04-29 Chinese
金陵药业股份有限公司关于召开2023年度网上业绩说明会的公告
Investor Presentation Classification · 95% confidence The document is an announcement about the scheduling of an online earnings presentation (业绩说明会) related to the company's 2023 Annual Report, which was already published and disclosed on April 30, 2024. The document invites investors to participate in the online meeting and submit questions. It does not contain the actual financial report or detailed financial data, but rather serves as a notice for an upcoming event to discuss the annual results. The document length is short (801 characters), and it references the annual report as already published. Therefore, this is an Investor Presentation announcement rather than the Annual Report itself or the Earnings Release. The best fitting category is Investor Presentation (IP).
2024-04-29 Chinese
金陵药业股份有限公司2023年度董事会工作报告
Board/Management Information Classification · 95% confidence The document is titled as the "2023 Annual Board of Directors Work Report" of Jinling Pharmaceutical Co., Ltd. It details the board's composition, governance practices, internal control, compliance, investor relations, and plans for 2024. It references the 2023 fiscal year and discusses the board's activities and oversight rather than presenting full financial statements or audit opinions. The document is a comprehensive report on the board's work and governance rather than a full annual report or audit report. It fits best under the category of Board/Management Information (MANG), which covers announcements and reports about changes and activities of the board of directors and senior management. The document length is 4578 characters, which is sufficient for a detailed report but does not contain full financial statements or audit results. Therefore, the classification is MANG with high confidence.
2024-04-29 Chinese
监事会决议公告
Regulatory Filings Classification · 95% confidence The document is a resolution announcement from the Supervisory Board of Jinling Pharmaceutical Co., Ltd. It details the meeting date, attendance, and the resolutions passed, including approval of the 2023 Supervisory Board Work Report, 2023 Financial Final Accounts Report, 2023 Profit Distribution Plan, Internal Control Self-Evaluation Report, and other related matters. The document repeatedly states that the detailed reports and documents are published separately on April 30, 2024, on designated websites and newspapers. The document itself does not contain the full financial statements or detailed reports but is an announcement of the meeting resolutions and references where the full reports can be found. The document length is relatively short (2653 characters), and it serves as a formal announcement of meeting decisions rather than the reports themselves. Therefore, according to the "Menu vs Meal" rule, this document is best classified as a Regulatory Filing (RNS) because it is a formal announcement of meeting resolutions and references other reports rather than containing the reports themselves.
2024-04-29 Chinese
内部控制审计报告
Audit Report / Information Classification · 95% confidence The document is titled as an internal control audit report for Jinling Pharmaceutical Co., Ltd. for the year ending December 31, 2023. It is issued by an accounting firm and contains an audit opinion on the effectiveness of internal controls over financial reporting. The content focuses on the audit of internal controls rather than a full annual report or financial statements. The document length is short (677 characters), but it contains the actual audit opinion and details, not just an announcement. This fits the definition of an Audit Report / Information (AR), which includes standalone audit reports and applied accounting principles. Therefore, the correct classification is AR. FY 2023
2024-04-29 Chinese

Browse filings by year

27 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.